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Background: The presence of autoantibodies has been proposed as evidence for a role of autoimmunity in autism.
This report investigates the prevalence of autoantibodies in children with autism using the luciferase immuno-
precipitation systems (LIPS) immunoassay technology. A panel of autoantibody targets against several known
and candidate neurological autoantigens, autoimmune-associated autoantigens and viruses was employed.
Methods: Serological analysis was performed on typically developing children (n= 55), developmentally delayed
childrenwithout autism (n= 24) and children diagnosedwith autism (n= 104). Autoantibodies weremeasured
against glutamic acid decarboxylase-65 (GAD65), a CNS autoantigen proposed to be associated with autism and
against Ro52, glial ﬁbrillary acidic protein, tyrosine hydroxylase, aquaporin-4, and gamma-enolase, the mouse
mammary tumor virus and the xenotropic murine leukemia virus. Antibody levels and seropositivity prevalence
were analyzed for statistically signiﬁcant differences between the three groups.
Results: The majority of the children (98%) were seronegative for all targets in the antigen panel. No GAD65
seropositive children were detected in the cohort. Several low level seropositive sera against several of the protein
targets were identiﬁed in isolated children in each of the three groups, but there was no difference in prevalence.
Conclusion:Using this panel of antigens and a sensitive, robust assay, no evidence of unusual immunoreactivitywas
detected in children with autism, providing evidence against a role of autoimmunity against several previously
implicated proteins in autism spectrum disorder pathogenesis.
General signiﬁcance: The idea that autoantibodies represent an underlying cause or are biomarkers for autism
pathophysiology is not supported by this report.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Autism spectrum disorder (ASD) is a behaviorally deﬁned
neurodevelopmental disorder [1]. The deﬁcits in social-communication
and the presence of restricted interests and repetitive behaviors result
in lifelong impairments and disability. ASD has been reported to affect
as many as 1 of 88 children in the US [2]. A variety of genetic and envi-
ronmental triggers have been proposed to be involved in causing autism
[3,4].
One focus of ASD pathophysiology involves a dysfunctional immune
response, which is based in part on the controversial ﬁndings of autoan-
tibodies in early fetal brain development or during the ﬁrst few years of
a child's life [5]. Likely contributing to often contradictory and conﬂicting
autoantibody results has been the use of immunoassay methodologies
measuring autoantibodies against undeﬁned antigens such as by).
ss article under the CC BY-NC-ND licimmunohistochemistry of brain tissue and Western blot of brain ex-
tracts using human serum [6–10]. Along these lines, a study by Singer
et al. found thatmore children with ASD demonstrated increased stain-
ing intensity on Western blots corresponding to a 100 kDa band in the
caudate, putamen and prefrontal cortex and for a 73 kDa band in the
cerebellum and cingulate gyrus compared to controls [6]. Another
group found immunoreactivity against a 52 kDa cerebellar protein as
themajor autoantigen species in ASD [7]. However, other studies exam-
ining autoantibodies in ASD and controls found no difference in immu-
noreactivity usingWestern blot analysis [9] and immunohistochemistry
of simian brain slices [10]. Thus, the relevance, if any, of autoantibodies
in ASD based on these methodologies remains unclear. Additionally,
speciﬁc antigen immunoassays have been used to measure autoanti-
bodies in ASD including autoantibodies against target proteins such as
glial ﬁbrillary acidic protein (GFAP), myelin basic protein (MBP) and
glutamic acid decarboxylase-65 (GAD65) [11–15]. Singh et al. reported
that subjects with ASD had a higher prevalence of autoantibodies
against GFAP compared to controls [14], yet another group found noense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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consistent reports have been reported for MBP [12,15]. Although auto-
antibodies against GAD65, an enzyme responsible for producing the
inhibitory transmitter gamma-aminobutyric acid, have also been re-
ported in subjects with ASD [13], these ﬁndings have yet to be
reproduced by others. Together the inconsistencies of the ﬁndings high-
light the need for employing more powerful immunoassay methodolo-
gies to clarify the frequency of autoantibodies in ASD.
Unlike ELISAs, ﬂuid-phase immunoassays are generally regarded as
the most sensitive and speciﬁc immunoassay format for identifying au-
toantibody responses and for the diagnosis of autoimmune diseases
[16]. The luciferase immunoprecipitation systems (LIPS) is a ﬂuid-
phase immunoassay employing deﬁned recombinant proteins
expressed as an in-frame fusion with the low molecular weight light-
emitting luciferase protein obtained from Renilla reniformis. LIPS per-
mits robust detection of antibodies against a variety of infectious and
autoimmune targets or panels of antigens from such diseases [17].
LIPS has shown high diagnostic performance for the diagnosis of auto-
immune diseases that includes type I diabetes [18,19], Sjögren's syn-
drome [20,21], systemic lupus erythematosus [22], myositis [23], anti-
cytokine associated diseases [24,25] and several autoimmune neurolog-
ical diseases such as stiff person syndrome [26–29]. In the current study,
LIPS was used to investigate whether ASD children had previously
reported autoantibodies against GAD65. In addition, antibodies were
evaluated against several other autoimmune-associated autoantigens,
candidate neurological autoantigens, and viral proteins. For most anti-
gens in this study, detection of autoimmune reactivity has been previ-
ously veriﬁed in earlier reports using appropriate patient groups in
which (a) the target antigen or autoantigens are known and (b) the
cohort contains patients positive for the clinical diagnosis and positive
for the target antibodies in their serum.
2. Methods
The cohort of children with ASD and controls were evaluated at the
National Institute of Mental Health, National Institutes of Health,
Bethesda, MD under institutional review board approved protocol
NCT00298246: Clinical and Immunological Investigations of Subtypes
of Autism. The children with ASD (n = 104; mean age = 4.3 yr;
SD = 1.3; range = 2.2–7.4 yrs), were diagnosed by Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th ed. (DSM IV) [30] after adminis-
tration of the Autism Diagnostic Observation Schedule [31] and the
Autism Diagnostic Interview (ADI-R), a semi-structured parent inter-
view concerning all domains of impairment in autism [32]. Typically de-
veloping children (n= 55) were used as a control group, (mean age =
3.3 yr; SD= 1.4; range= 1.3–7.6 yrs). A control group of developmen-
tally delayed children without autism (n= 24) was also employed and
was approximately matched on a developmental level to the autistic
group (mean age = 4.3 yr; SD = 1.2; range = 2.7–7.6 yrs). Lastly, fol-
lowing antibody evaluation of the cohort, one sample was excluded
from the analysis. This sample, from a subject with ASD, had unusual
immunoreactivity against ﬁve of the six proteins. It appeared that the
polyreactive serum recognized theRenilla luciferasewhich is the report-
er enzyme in LIPS antibody test and so, the sample was excluded from
consideration, leaving 103 samples in the ASD group.
Previously described LIPS tests were employed to detect autoanti-
bodies against GAD65, Ro52, GFAP, aquaporin-4 (AQP-4), and tyrosine
hydroxylase (TH) [18,19,22]. Three additional new antigen constructs
for gamma-enolase (γ-enolase, neuron speciﬁc enolase), the gag pro-
tein from xenotropic murine leukemia virus (XMRV) and p24 from
mouse mammary tumor virus (MMTV) were generated in the pREN2
vector [26] as C-terminal Renilla luciferase antigen fusions. γ-Enolase
was chosen as a potential target based on its high expression in neurons
and reports of it being an autoantigen target in post-streptococcal auto-
immune CNS disease [33]. MMTV is a potential zoonotic infection in
humans [34] and XMRV infection was reported to cause chronic fatigue[35]. Both the γ-enolase and MMTV p24 were ampliﬁed by PCR using
commercial cDNA plasmids. The XMRV gag protein was generated by
synthetic gene synthesis (Blue Heron, Bothell, WA) using optimized
human codons. The three new expression constructs were veriﬁed by
sequencing and details of their construction are available upon request.
LIPS testing was performed as previously described [18,19]. Light
units were measured in a Berthold LB 960 Centro luminometer
(Berthold Technologies, Germany) using coelenterazine substrate mix
(Promega, Madison, WI). In some cases, control sera samples from
type I diabetes patients and systemic lupus erythematosus were used
as known positive controls. Seropositivity status for GAD65, Ro52,
GFAP, AQP-4 and TH was based on known cut-offs. For the three new
autoantigens (γ-enolase, gag XMRV and p24 MMTV), cut-off values
were assigned based on the mean plus three standard deviations of
the typically developing children controls. Researchers were blinded
to patient diagnosis during analysis.
The non-parametric Mann–Whitney U statistical test was used for
comparison of antibody levels in the three different groups. For compar-
ing the seroprevalence of antibody responses in the different groups,
contingency tables were generated and analyzed using the Fisher
exact test for statistical signiﬁcance.
3. Results
Based on the report that children with ASD have GAD65 autoanti-
bodies [13], LIPS was used tomeasure autoantibodies against this target
in a cohort with ASD. As described in the Methods section, three sera
from subjects with Type I diabetes, an autoimmune disease known to
generate anti-GAD65 autoantibodies, were employed as positive con-
trols (17–19). As expected, the three type I diabetes sera showed highly
elevated levels of GAD65 autoantibodies all above the established cut-
off (Fig. 1A). However, testing of serum from the typically developed
children (n=55), developmentally delayed children (n=24) and chil-
dren with ASD (n= 103) demonstrated no seropositive autoantibodies
to GAD65: all measured LU values were below the cut-off (Fig. 1A). To
determine if the ASD children might have a lupus-like autoimmune
phenotype, the LIPS Ro52 autoantibody test was employed (20–23). In
contrast to three positive control samples from subjects with systemic
lupus erythematosus, none of the children in the ASD cohort showed
seropositivity with Ro52. All values were below the known cut-off
(Fig. 1B). It should be noted that LIPS tests for both GAD65 and Ro52
detected antibody levels in the positive control samples that were
often 10–1000-fold higher than the control and ASD samples. Therefore,
any subtle low positivity, if present in the cohort, should have been
detected (Fig. 1). These ﬁndings rule out the possibility that GAD65
and Ro52 autoantibodies are biomarkers of ASD.
Autoantibodies against several other known or potential auto-
antigen targets, including GFAP, TH, γ-enolase and AQP-4 (the
autoantigen in neuromyelitis optica), were also measured by LIPS in
the three groups. In certain individuals, occasional sporadic, low-level
seropositive autoantibodies against the four proteins were detected.
For example, two of the 55 typically developing, two of the 25 develop-
mental delayed and four of the 103 ASD children were seropositive,
exhibiting low levels of autoantibodies to GFAP (Table 1). However, sta-
tistical analysis of the GFAP seropositivity by Fisher's exact testing with
contingency tables revealed no signiﬁcant differences in seroprevalence
between the three groups. Similar analyses for autoantibodies against
AQP-4, TH, and γ-enolase also revealed occasional weak seropositivity
in the children, but no signiﬁcant increase in seropositivitywas detected
in ASD (Table 1).
Based on the known ability of LIPS to detect robust antibodies to the
capsid proteins from HIV [36] and HTL-I retroviruses [37], we explored
the possibility of detecting antibodies against two capsid proteins
derived from MMTV and gag of XMRV in the cohort. Based on a cut-off
derived from the healthy control children, no signiﬁcant immunoreac-
tivities were detected in any of the ASD or other children (Table 1).
Fig. 1. Lack of autoantibodies against GAD65 and Ro52 in the ASD cohort. Autoantibody levels were evaluated for (A) GAD65 and (B) Ro52 in the cohort. Additional positive control serum
samples from type I diabetes and systemic lupus erythematosus subjects were included for the detection of GAD65 and Ro52 autoantibodies, respectively. The light units (LU) plotted on
the y-axis using a log10 scale measure the autoantibody levels for each sample. The dotted lines represent the cut-off values for determining seropositivity for each autoantigen.
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Primarily, we attempted to reproduce previous reports showing a
high prevalence of GAD-65 autoantibodies in children with ASD. For
our investigation, a validated GAD-65 LIPS test that performs with the
same high sensitivity and speciﬁcity as the gold-standard radiolabel
binding immunoassay was employed [18]. Using this LIPS assay, posi-
tive control clinical serum samples were used to conﬁrm the capacity
of LIPS to detect autoantibodies against GAD65. However, no seroposi-
tive GAD65 autoantibodies were detected in any of the children from
the autism cohort, which was unlike the earlier study that detected
15% seropositivity in an ASD cohort [13]. One likely explanation for
this discrepancy in GAD65 prevalence in ASD is that the previous
study used a solid-phase ELISA. This test format, in which target antigen
proteins are bound to the ELISA plate, is known to be susceptible to non-
speciﬁc reactivities [16]. Thus, it is possible that the reactivity to GAD65
in earlier ELISA-based studies was a result of such non-speciﬁc signals.
Antibodies against several other autoantigens also show no associa-
tionwith ASD. The lack of autoantibodies against Ro52, a commonly de-
tectable target of autoantibodies in lupus [22], rules out a lupus-like
neurological phenotype in ASD. Thisﬁnding also eliminates the possibil-
ity that Ro52 is the 52 kDa target antigen seen in ASD sera by Western
blotting [7]. Additionally, no evidencewas found supporting a role of in-
creased prevalence of GFAP autoantibodies in ASD, which is in agree-
ment with a previous study [11]. Speciﬁcally, 1% and 2%, of the ASD
and control groups, respectively, showed GFAP seropositivity, but the
absolute levels were low. Thus, both a neuronal and a glial autoantibody
either were not present or their prevalence was not elevated in ASD
subjects. No differences between the three groups were found for the
prevalence of autoantibodies against AQP-4, tyrosine hydroxylase or
neuron-speciﬁc γ-enolase. The lack of autoantibodies against AQP-4,Table 1
Prevalence of antibodies in the autism cohort.
Antigen Typically developing
(N = 55) seropositivity
Developmental delay
(N = 25) seropositivity
ASD (N = 103)
seropositivitya
GAD-65 0/55 0/25 0/103
Ro52 0/55 0/25 0/103
GFAP 2/55 2/25 4/103
AQP-4 3/55 0/25 5/103
TH 1/55 0/25 1/103
γ-Enolase 1/55 0/25 2/103
XMRV gag 1/55 0/25 0/103
MMTV p24 1/55 0/25 0/103
a Fisher exact tests revealed no statistical difference in prevalence of antibodies against
the eight targets in ASD compared to typically developing and developmental delay
children.an astrocytic protein involved withmaintenance of the blood brain bar-
rier and a pathognomonic autoantibody in neuromyelitis optica rules
out this target as a potential source of autoimmune blood brain barrier
disruption in ASD. Moreover, seropositivity to the neuron-speciﬁc
γ-enolase was found in 1% and 2%, of the ASD and control groups, re-
spectively, but again the absolute levels were low. Also, no difference
was seen between the three groups for TH autoantibodies. Thus, two
more neuronal autoantibody targets either were not present or their
prevalence was not elevated in ASD subjects. TH is particularly relevant
since it is the ﬁrst enzyme in the biosynthetic pathway for the catechol-
amines dopamine and norepinephrine, which aremajor neurotransmit-
ters in circuits subserving affect and attention. Similar to our GFAP
observations there are occasional sporadic low level signals to several
of these targets that likely reﬂect uncharacterized immune responses.
Two possible viral targets, MMTV and XMRV, also showed no signif-
icant immunoreactivity in the cohort. The fact thatwe did not detect an-
tibodies against XMRV in autism using LIPS is also in agreement with
two other reports [38,39],whichusedmainly polymerase chain reaction
molecularmethods for detection. Thus, three independent reports using
different methodologies do not support detection of the XMRV artifact
in ASD. Despite no evidence for a role of XMRV or MMTV, additional
studies are needed to determine if other infectious agents, or the body's
response to such infections agents, might play a role.
From the results presented here, we conclude that autoantibodies
against GAD65 and the other targets that we tested are unlikely to be
signiﬁcant contributors to autism spectrum disorder. However, given
the limited number of antigens examined, it is possible there are other
neurological antigens and target proteins which might targets of hu-
moral responses in ASD. It would be worthwhile to explore the immu-
noreactivity reported in ASD by several groups that employed
Western blot [7] and immunohistochemical techniques [7,40] by using
high sensitivity LIPS assays. These investigations would ﬁrst require
that the antigens be identiﬁed, in order that deﬁned recombinant pro-
teinsmight be used to construct quantitative immunoassays for analysis
of a large number of controls and ASD subjects. The presence of an
autoimmune component in ASD is an important question to resolve in
a deﬁnitive fashion. The data presented in this report suggest that
newer more speciﬁc and deﬁnedmethodologies can make a substantial
contribution to realizing this goal.
5. Conclusions
This study employed a ﬂuid-phase immunoassay, LIPS, which shows
high diagnostic performance for autoantibodies present in multiple
autoimmune disorders and for infectious agents. Using this assay, we
found no evidence of autoantibodies against GAD65 and several other
84 S. Kalra et al. / BBA Clinical 4 (2015) 81–84autoantigens in children with autism spectrum disorder. No antibodies
were detected against two retroviruses, MMTV or XMRV. These results
suggest that autoimmunity against the tested neuronal, astrocytic, and
other proteins is not likely a causative factor or diagnostic biomarker
in autism.
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